Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.

Inflammation research : official journal of the European Histamine Research Society ... [et al.] - 8 Jan 2026

Tian Faqing, Wang Jinxing, Zhang Pengwei, Jiang Jian, Cheng Xiaohui, Li Juheng, Tang Meiqin, Fan Jiaoyang, Yan Pu, Zhao Guoxin

Abstract excerpt

OBJECTIVE: TP53 mutations are infrequently found in multiple myeloma (MM), a malignancy characterized by the clonal proliferation of plasma cells that secrete monoclonal immunoglobulin. This study explored the mechanism of caspase-activated DNase (CAD) and B-cell lymphoma 2 (BCL-2) in regulating proliferation and drug resistance of TP53-mutant MM cells. METHODS: TP53 wild-type (H929) and TP53-mutant (U266 and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bortezomib

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Deoxyribonucleases

Share to Drug Resistance, Neoplasm

Share to Gene Knockdown Techniques

Share to Multiple Myeloma

Share to Proto-Oncogene Proteins c-bcl-2

Share to Tumor Suppressor Protein p53

Source

Identifiers

PMID: 41504908
DOI: 10.1007/s00011-025-02151-z

Genes

CAD
TP53
ABCB1
ABCG2
CDK1
CCK

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Knockdown of caspase-activated DNase and B-cell lymphoma 2 inhibits cell proliferation and drug resistance in TP53-mutant multiple myeloma.PMID 41504908Read ↗

RITA Inhibits Multiple Myeloma Cell Growth through Induction of p53-Mediated Caspase-Dependent Apoptosis and Synergistically Enhances Nutlin-Induced Cytotoxic ResponsesSemantic proximity Read ↗

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma.Semantic proximity Read ↗

Drug Resistance to Inhibitors of the Human Double Minute-2 E3 Ligase Is Mediated by Point Mutations of p53, but Can Be Overcome with the p53 Targeting Agent RITASemantic proximity Read ↗

Targeting an MDM2/MYC Axis to Overcome Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Autophagy and Apoptosis: Current Challenges of Treatment and Drug Resistance in Multiple MyelomaSemantic proximity Read ↗

Mechanisms of action of the BCL-2 inhibitor venetoclax in multiple myeloma: a literature reviewSemantic proximity Read ↗

Hierarchy for targeting prosurvival BCL2 family proteins in multiple myeloma: pivotal role of MCL1Semantic proximity Read ↗

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read ↗

Cyclin D1 sensitizes myeloma cells to endoplasmic reticulum stress-mediated apoptosis by activating the unfolded protein response pathwaySemantic proximity Read ↗

Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome.Semantic proximity Read ↗

Curcumin induces cell death of the main molecular myeloma subtypes, particularly the poor prognosis subgroupsSemantic proximity Read ↗

ABT-737 is highly effective against molecular subgroups of multiple myelomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.